Nanotechnology Platform for Drug Delivery and Targeted Therapeutic Nanomedicine
 

About Us


The company, nanoDERM Sciences, Inc.
(nDS), is a Maryland based early stage
therapeutic products developer. nDS is also a
member of the Institute for Life Science

The company, nanoDERM Sciences, Inc. (nDS), is an infectious disease and wound management company focused on the development and commercialization of advanced platform wound healing and drug delivery nanotechnology. nDS improves patient outcomes using an advanced platform wound healing solution (and various therapeutic agents) delivered in a more controlled manner than current technology.


The focus of the nDS R&D plan is to protect, expand, and develop the patented drug delivery platform to combat multidrug resistant bacteria and other unmet high priority medical needs.

The company, nanoDERM Sciences, Inc.
(nDS), is a Maryland based early stage
therapeutic products developer. nDS is also a
member of the Institute for Life Science
The company, nanoDERM Sciences, Inc.
(nDS), is a Maryland based early stage
therapeutic products developer. nDS is also a
member of the Institute for Life Science
The company, nanoDERM Sciences, Inc.
(nDS), is a Maryland based early stage
therapeutic products developer. nDS is also a
member of the Institute for Life Science

Management Team


CEO:   Roy R. Yeoman III
V.P. and Director of R&D: duane R. Hospenthal, BS, MS, PhD, MD, FACP, FIDSA
CMO: Duane R. Hospenthal, BS, MS, PhD, MD
CSO:  Jian Du PhD
CFO:   Gene Townsend
Surgical Consultant: Glenn W. Geelhoed, MD